Annals of Case Reports and Clinical Studies (ISSN: 2834-5673) | Volume 3, Issue 2 | Case Report | Open Access DOI
Daniel Ubokudom*
Daniel Ubokudom1*, Unwam Jumbo2, Ovie Okorare3, Akanimo Antia4
1Department of Internal Medicine Thomas Hospital, USA
2Department of Internal Medicine Thomas Hospital, USA
3Department of Internal Medicine, Vassar Brothers Medical Centre, Nuvance Health, NY, USA
4Department of Internal Medicine, Lincoln Medical Centre, NY, USA
*Correspondence to: Daniel Ubokudom
Fulltext PDFChronic Lymphocytic leukemia is one of the lymphoproliferative disorders and most prevalent in the adult population presenting most times as an incidental finding of lymphocytosis on a routine blood count. However, a minute amount of the population presents with unintentional weight loss, fevers of > 100.5 F, drenching night sweats without evidence of infection. Most Patients with Chronic Lymphocytic Leukemia do not require treatment as they have survival rates similar to the general population. Tyrosine kinase inhibitors have been at the fore front of treating CLL. Cases of tyrosine kinase inhibitor induced pleural effusion has been described in the literature but no case has been identified in patients with Chronic lymphocytic leukemia in remission. We hereby present a case of Acalabrutinib Induced Pleural Effusion in a Patient with CLL in remission.
Daniel Ubokudom, Unwam Jumbo, Ovie Okorare, Akanimo Antia. A Rare Case of Acalabrutinib Induced Pleural Effusion in a Patient with Chronic Lymphocytic Leukemia in Remission. Ann Case Rep Clin Stud. 2024;3(2):1-3.